Literature DB >> 29272893

Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis.

Eric F Martin1,2, Cynthia Levy2.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease that often progresses to secondary biliary cirrhosis and end-stage liver disease. Short of liver transplantation (LT), there is no effective treatment for PSC. PSC accounts for approximately 5% of total adult LTs in the US and is currently the fifth most common indication for LT. Patient and graft survival for PSC is among the highest for all indications for LT. The main factors that impact outcomes after LT for PSC include biliary strictures, rejection, and recurrence of PSC. Recurrent PSC (rPSC) develops in 20% of LT recipients within 5 years of LT and is associated with negative patient and graft survival. LT is a viable option for recipients who develop rPSC and progress to graft failure. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2017        PMID: 29272893     DOI: 10.1055/s-0037-1608655

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  4 in total

Review 1.  Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture.

Authors:  Jawad Ahmad
Journal:  Hepatol Int       Date:  2018-11-14       Impact factor: 6.047

Review 2.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 3.  Post-Transplant Disease Recurrence in Pediatric PSC.

Authors:  Nisreen Soufi; Fateh Bazerbachi; Mark Deneau
Journal:  Curr Gastroenterol Rep       Date:  2018-08-06

4.  Primary Sclerosing Cholangitis Complicated with Aphthoid Colitis Difficult to Diagnose from IgG4-Related Sclerosing Cholangitis.

Authors:  Jin Imai; Hitoshi Ichikawa; Motoki Kaneko; Hiroyuki Ito; Shinji Takashimizu; Takayuki Shirai; Takuma Tajiri; Norihito Watanabe; Hidekazu Suzuki
Journal:  Case Rep Gastroenterol       Date:  2022-02-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.